- Curaleaf Holdings (CSE:CURA) has been approved as a Clinical Registrant in the US state of Pennsylvania
- The approval was issued by the Commonwealth’s Department of Health, Office of Medical Marijuana
- Under the medical marijuana research program Curaleaf will be free to open a cultivation and processing facility, and up to six dispensaries
- Shares in the company are currently down 0.88 per cent to C$7.91, with a market cap of C$3.73 billion
Curaleaf Holdings (CSE:CURA) has announced its approval as a Clinical Registrant in Pennsylvania.
The company is a multi-state cannabis operator, with operations on both the East and West coasts of the United States.
Issued by the Department of Health, the approval will allow Curaleaf to open a cultivation and processing facility, and up to six dispensaries in the state.
In turn, the company will support research initiatives via the provision of medical cannabis, general expertise and distribution to relevant patients.
“This research is essential to providing physicians with more evidence-based research to make clinical decisions for their patients,” said the Department of Health’s Dr. Rachel Levine.
“It is the cornerstone of our program and the key to our clinically based, patient- focused program for those suffering with cancer, PTSD and other serious medical conditions.”
Curaleaf currently operates 53 dispensaries in 14 US states, with 15 cultivation and 24 processing sites.
The company’s CEO, Joseph Lusardi, thanked the Pennsylvania Department of Health and confirmed the company’s commitment to research and medical patients.
“Curaleaf has always been focused on high-quality cannabis products, as well as superior patient care and education,” he said.
“We look forward to contributing to medical research that will ultimately benefit not only the residents of the Commonwealth, but the entire country.”
Shares in Curaleaf are currently down 0.88 per cent to C$7.91, with a market cap of C$3.73 billion.
